Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two doses of either the Pfizer or Oxford-AstraZeneca vaccine offer similar protection against symptomatic SARS-CoV-2 infection to that coming from natural immunity after infection, an ongoing study of healthcare workers has found.

OUH’s Chief Nurse, Sam Foster, delivers a Pfizer vaccine to a member of staff

None of the 1,456 healthcare workers at Oxford University Hospitals (OUH) NHS Foundation Trust who had received two vaccines had a symptomatic infection when followed up more than 14 days after their second vaccination. The same high level of protection was seen in unvaccinated healthcare workers who had contracted COVID-19 naturally; they had 98% fewer symptomatic infections than unvaccinated individuals who had not been infected before.

Most of the healthcare workers studied had only received one vaccine to date. Protection against symptomatic infection was lower – at 67% – after a first dose of vaccine – received by 11,023 hospital staff.

The findings were the latest data from ongoing analysis of symptomatic and asymptomatic staff testing for SARS-CoV-2 at OUH’s four hospitals and associated facilities. In total, 13,109 healthcare workers have participated.

Of these, 8,285 have received the Pfizer-BioNTech vaccine (1,407 of them two doses) and 2,738 the Oxford-AstraZeneca vaccine (49 of them receiving both doses).

Read the full story on the NIHR Oxford Biomedical Research Centre website

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.